| (19) |
 |
|
(11) |
EP 2 228 056 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
03.08.2011 Bulletin 2011/31 |
| (43) |
Date of publication A2: |
|
15.09.2010 Bulletin 2010/37 |
| (22) |
Date of filing: 22.02.2010 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO SE SI SK SM TR |
|
Designated Extension States: |
|
AL BA RS |
| (30) |
Priority: |
09.03.2009 US 158440
|
| (71) |
Applicant: Sanochemia Pharmazeutika AG |
|
1091 Wien (AT) |
|
| (72) |
Inventors: |
|
- Welzig, Stefan
1030 Wien (AT)
- Rothenburger, Jan
7064 Oslip (AT)
- Kälz, Beate
7035 Steinbrunn (DE)
- Gungl, József
9400 Sopron (HR)
- Gerdes, Klaus
40233 Düsseldorf (DE)
|
| (74) |
Representative: Dungler, Karin |
|
Beer & Partner
Patentanwälte KG
Lindengasse 8
1070 Wien
1070 Wien (AT) |
|
| |
|
| (54) |
Tolperisone controlled release tablet |
(57) The invention refers to a GRDDS (Gastro Retentive Drug Delivery System) containing
tolperisone and having a 4-MMPPO fraction of less than 1.5 ppm for the extended release
of the active substance tolperisone while avoiding the formation of 4-MMPPO in the
gastrointestinal tract.